All lobbying filings

Rare Disease Company Coalition

Rare Disease Company Coalition filed a Q4 report for Rare Disease Company Coalition on January 20, 2026.

Lobbying for Rare Disease Company Coalition · Healthcare

As filed: RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION.

All filings by Rare Disease Company Coalition · Everything Rare Disease Company Coalition has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$70,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Trade (domestic/foreign)

BIS-2025-0022 - Rare Disease Exemption for Pharmaceutical Tariffs CMS-5545-P - Rare Disease Exemption from GLOBE Model CMS-5546-P - Rare Disease Exemption from GUARD Model

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals

Bills named in this filing 1

H.R. 1262
Mikaela Naylon Give Kids a Chance Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.